EU Offers Flexibility On UK Batch Release In No-Deal Brexit Scenario
Executive Summary
The UK has been offered an exemption from the requirement for UK medicines to undergo EU batch testing and release before they can be marketed in member states of the EU, but only in specific circumstances.
You may also be interested in...
Brexit Relief For Pharma As EMA Grants Most Batch Testing Exemptions
Of the 60 or so applications the European Medicine Agency has received from drug companies hoping for more time to move their batch testing sites from the UK to the EU, about 50 have been successful.
UK Offers Pharma Firms Ferry Tickets To Avoid No-Deal Brexit Supply Disruptions
The UK health department says it has purchased ferry tickets that pharmaceutical companies can buy in order to transport their medicines and other product using alternative shipping routes between EU and UK ports in the event of a no-deal Brexit. It has also updated companies on how they can access additional warehousing space for medicine stockpiles.
EMA Urges Speed For Brexit-Related Variations Submissions
As the UK’s departure from the EU nears, the European Medicines Agency has published more guidance for companies that are planning to submit Brexit-related Type IA and Type IB variations.